Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 437 results found. Search for [ Serum Institute of India vaccine trials ]

Results 80 to 100 of 437
BusinessToday.In
January 20, 2021
Bharat Biotech is developing the intranasal vaccine in partnership with the Washington University School of Medicine and US-based vaccine maker Ocugen


PTI
January 18, 2021
Tata Steel, ArcelorMittal Nippon Steel India and Rashtriya Ispat Nigam Ltd said they will continue to support the government in the nationwide drive and will wait till vaccines are available for corporates


PTI
January 16, 2021
Speaking at the 25th Wharton India Economic Forum, he said the Indian pharma industry ensured the continuity of supplies


Reuters
January 14, 2021
As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)


BusinessToday.In
January 12, 2021
Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine


Rajeev Dubey | Vivek Punj
January 11, 2021
Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers


BusinessToday.In
January 8, 2021
Bharat Biotech chairman Krishna Ella says this nasal vaccine will revolutionise Indian vaccine making capabilities and help it leapfrog along with Europe, the US and China


Manoj Sharma | Mudit Kapoor
January 7, 2021
Initial 30 crore vaccinations (60 crore doses) planned by the Centre would have cost Rs 13,200 crore. However, need for 66 crore doses raises the cost by Rs 1320 crore


Rajeev Dubey
New Delhi, January 6, 2021
Dr Krishna Ella, Chairman of Bharat Biotech, said that unlike the clinical trials of AstraZeneca vaccine (which has been licensed to Serum Institute of India), Bharat Biotech did not try to suppress the side effects of vaccine by giving paracetamol to the volunteers. He also said that for his company safety came first. Watch him in conversation with Rajeev Dubey, Editor, Business Today.Also Read: China denies entry to WHO team investigating COVID-19 origins


BusinessToday.In
January 5, 2021
Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial


Manoj Sharma
January 5, 2021
There was immense pressure on governments to develop a vaccine at the earliest due to the destruction COVID-19 pandemic was unleashing. This led to a race among pharma companies to be the first to develop a vaccine


BusinessToday.In
January 5, 2021
COVID-19 vaccine update: India has approved two coronavirus vaccines for emergency use - Bharat Biotech-ICMR's Covaxin and Covishield manufactured by Pune's Serum Institute


Joe C Mathew
January 4, 2021
Krishna Ella, Chairman of Bharat Biotech, said that unlike the clinical trials of AstraZeneca vaccine, Bharat Biotech did not try to supress the side effects of vaccine by giving paracetamol to the volunteers


BusinessToday.In
January 4, 2021
SII CEO Adar Poonawalla said that the company will start selling the Covishield to the Indian government and GAVI (Global Alliance for Vaccines and Immunisation) nations in the first stage, followed by the private market


BusinessToday.In
January 4, 2021
Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India


BusinessToday.In
January 4, 2021
Both the vaccines got approval for emergency use authorisation on Sunday. They're both administered in two doses, the DCGI said in the permission letter


BusinessToday.In
January 4, 2021
Coronavirus vaccine in India: Adar Poonawalla, CEO of Serum Institute of India that is manufacturing Covishield had said that the company is ready to roll out its vaccine in the coming weeks


BusinessToday.In
January 4, 2021
The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults


BusinessToday.In
January 3, 2021
The ICMR head emphasised that the scientists at ICMR have been successfully able to culture the UK strain and the efficacy of Covaxin against it will be further tested in days to come


BusinessToday.In
January 3, 2021
Calling it a great day for the country, AIIMS Director Dr Randeep Guleria said that initially Serum-AstraZeneca's Covishield will be administered to the people


PAGES 5 OF 22  12345